<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243932</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA1536</org_study_id>
    <secondary_id>R01NS048125</secondary_id>
    <nct_id>NCT00243932</nct_id>
  </id_info>
  <brief_title>Clinical Trial of High Dose CoQ10 in ALS</brief_title>
  <official_title>Clinical Trial of High Dose CoQ10 in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in
      individuals with ALS for a possible future phase III study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a progressive and devastating neurodegenerative
      disorder. Available treatment for ALS remains scarce. Oxidative stress and mitochondrial
      dysfunction have been implicated in the pathophysiology of ALS. Oxidative stress refers to
      the effects of cell-damaging reactive oxygen species, also known as free radicals. Oxidative
      stress is thought to contribute to nerve cell loss in ALS. Mitochondria are organelles within
      each cell that are sometimes called &quot;powerhouses of the cell&quot; because cellular energy
      metabolism is located within the mitochondria.

      Coenzyme Q10 (CoQ10), a mitochondrial cofactor known for its antioxidant properties, has
      prolonged survival in the mouse model of ALS and has slowed functional decline in another
      neurodegenerative disorder, Parkinson's disease. The goals of this double-blind,
      placebo-controlled, two-dose comparison phase II study are to obtain preliminary efficacy
      data and to select the preferred dose for a larger phase III study.

      Participants were randomly assigned to CoQ10 (at two different dose levels) or placebo in the
      first stage, then the 2,700 mg dose was selected in the second stage. Duration of the trial
      was 9 months with a total of 7 visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.</measure>
    <time_frame>9 months</time_frame>
    <description>The ALSFRSr, a questionnaire-based scale assessing daily living function ranging from 48 (best score) to 0 (worst), was administered to the patient, or to a proxy if the patient could not communicate effectively. Decline was defined as ALSFRSr at baseline minus ALSFRSr at month 9. Thus a positive value indicates worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Lou Gehrig's Disease</condition>
  <arm_group>
    <arm_group_label>2,700 mg CoQ10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1,800 mg CoQ10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>coenzyme Q10</intervention_name>
    <description>antioxidant and mitochondrial cofactor, given in capsules three times daily</description>
    <arm_group_label>2,700 mg CoQ10</arm_group_label>
    <arm_group_label>1,800 mg CoQ10</arm_group_label>
    <other_name>Coenzyme Q 10</other_name>
    <other_name>CoQ10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of definite, probable, or laboratory-supported probable ALS

          -  Negative pregnancy test for women of childbearing age and adequate birth control
             measures

          -  Subjects must be able and willing to give informed consent and must be capable of
             complying with the trial procedures

          -  Forced Vital Capacity (FVC) &gt;/= 60% of predicted

          -  Age 21 to 85 years, inclusive

          -  Disease duration of less than 5 years

          -  Subjects may take riluzole (without change in dose for more than 30 days before
             enrollment)

          -  Patients who have taken CoQ10 in the past will be eligible if they stop at least 30
             days before enrollment

          -  Patients who have taken vitamin E in the past will be eligible if they stop at least
             14 days before enrollment

        Exclusion Criteria:

          -  Dependency on mechanical ventilation (non-invasive ventilation &gt; 23 hours)

          -  Severe and unstable concomitant medical or psychiatric illness

          -  Insufficiently controlled diabetes mellitus

          -  Concomitant warfarin therapy

          -  Women who are breast feeding or have a high likelihood of pregnancy

          -  Significant hepatic dysfunction

          -  Forced Vital Capacity (FVC) less than 60%

          -  Exposure to CoQ10 within 30 days of enrollment

          -  Exposure to other experimental medications within 30 days of enrollment

          -  Exposure to vitamin E within 14 days of enrollment

          -  Sensitivity to color additive FD&amp;C Yellow No. 5

          -  Sensitivity to aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Kaufmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor, Division of Neuromuscular Disease, Columbia University Medical Center (Clinical Principal Investigator)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. L. P. Thompson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Statistical Analysis Center, Department of Biostatistics, Mailman School of Public Health (Statistical Principal Investigator)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hiroshi Mitsumoto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wesley J. Howe Professor of Neurology at the New York Presbyterian Hospital/Columbia University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences, Department of Neurology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences, Dept of Neurology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine, Department of Neurology</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University, Department of Neurology,</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago, Department of Neurology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Dept of Neurology, College of Medicine</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital , Department of Neurology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center, Division of Critical Care Research</name>
      <address>
        <city>Springfield,</city>
        <state>Massachusetts</state>
        <zip>01101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Medical Research Foundation, ,</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine, Department of Neurology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Medical Center, The Neurological Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical, Neurology Department</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University, Dept of Neurology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas, Health Science Center at San Antonio, Division of Neurology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont, Neurology Department</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B; QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009 Aug;66(2):235-44. doi: 10.1002/ana.21743.</citation>
    <PMID>19743457</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2005</study_first_submitted>
  <study_first_submitted_qc>October 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2005</study_first_posted>
  <results_first_submitted>March 29, 2010</results_first_submitted>
  <results_first_submitted_qc>February 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2011</results_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Hiroshi Mitsumoto</investigator_full_name>
    <investigator_title>Wesley J. Howe Professor of Neurology at the New York Presbyterian Hospital/Columbia University Medical Center</investigator_title>
  </responsible_party>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <keyword>CoQ10</keyword>
  <keyword>coenzyme Q10</keyword>
  <keyword>antioxidants</keyword>
  <keyword>free radicals</keyword>
  <keyword>mitochondrial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomized between April, 2005 and May, 2007. The last participant completed the trial March 2008.</recruitment_details>
      <pre_assignment_details>Exclusion criteria were forced vital capacity (FVC) of less than 60%, severe medical illness, or disease onset more than 5 years before study entry.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>2700mg CoQ10</title>
          <description>35 subjects from stage 1 + 40 new subjects; all taking 2,700mg CoQ10 - total 75.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>35 subjects from stage 1 + 40 new subjects; all receiving placebo - total 75.</description>
        </group>
        <group group_id="P3">
          <title>1,800 mg CoQ10</title>
          <description>35 patients. This dose group was discontinued after stage 1; only the 2,700 mg group was compared with placebo in the efficacy analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1: Dose Selection</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stage 2: Efficacy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40">40 newly randomized pts. Efficacy analysis included Stage 1 + Stage 2 patients</participants>
                <participants group_id="P2" count="40">40 newly randomized pts. Efficacy analysis included Stage 1 + Stage 2 patients</participants>
                <participants group_id="P3" count="0">No new pts. randomized because selection procedure in Stage 1 selected the 2,700 mg dose.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2700mg CoQ10</title>
          <description>35 subjects from stage 1 + 40 new subjects; all taking 2,700mg CoQ10 - total 75.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>35 subjects from stage 1 + 40 new subjects; all receiving placebo - total 75.</description>
        </group>
        <group group_id="B3">
          <title>1,800 mg CoQ10</title>
          <description>35 patients. This dose group was discontinued after stage 1; only the 2,700 mg group was compared with placebo in the efficacy analysis.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="10.8"/>
                    <measurement group_id="B2" value="56.9" spread="11"/>
                    <measurement group_id="B3" value="58.9" spread="12.5"/>
                    <measurement group_id="B4" value="56.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>The Change Over 9 Months in Forced Vital Capacity; Fatigue Severity Scale; Short Form-36; and 8OH2dG (a Biomarker of Oxidative Stress Measured in a Blood Sample).</title>
        <time_frame>9 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.</title>
        <description>The ALSFRSr, a questionnaire-based scale assessing daily living function ranging from 48 (best score) to 0 (worst), was administered to the patient, or to a proxy if the patient could not communicate effectively. Decline was defined as ALSFRSr at baseline minus ALSFRSr at month 9. Thus a positive value indicates worsening.</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2700mg CoQ10</title>
            <description>40 new subjects and 35 subjects from stage 1 all taking 2,700mg CoQ10 - total 75.
Stage 1 - 35 participants per group compared CoQ10 doses of 1,800mg and 2,700 mg/day and placebo.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>40 new subjects plus 35 subjects from stage 1 receiving placebo - total 75.</description>
          </group>
          <group group_id="O3">
            <title>1,800 mg CoQ10</title>
            <description>35 patients. Mean and SD are presented but this group was not included in the efficacy analysis because the 1,800 mg dose was discontinued after stage 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the ALS Functional Rating Scale-revised (ALSFRSr) Score.</title>
          <description>The ALSFRSr, a questionnaire-based scale assessing daily living function ranging from 48 (best score) to 0 (worst), was administered to the patient, or to a proxy if the patient could not communicate effectively. Decline was defined as ALSFRSr at baseline minus ALSFRSr at month 9. Thus a positive value indicates worsening.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="75"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.80" spread="7.34"/>
                    <measurement group_id="O2" value="9.44" spread="8.82"/>
                    <measurement group_id="O3" value="10.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: 2,700mg CoQ10 is at least 20% superior to placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>futility (non-superiority)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>2700mg CoQ10</title>
          <description>35 subjects from stage 1 + 40 new subjects; all taking 2,700mg CoQ10 - total 75.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>35 subjects from stage 1 + 40 new subjects; all receiving placebo - total 75.</description>
        </group>
        <group group_id="E3">
          <title>1,800 mg CoQ10</title>
          <description>35 patients. This dose group was discontinued after stage 1; only the 2,700 mg group was compared with placebo in the efficacy analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, GI</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="75"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Peg placement</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="75"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="75"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="75"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="42" subjects_affected="21" subjects_at_risk="75"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="75"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="244" subjects_affected="50" subjects_at_risk="75"/>
                <counts group_id="E2" events="231" subjects_affected="51" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue - Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology - Other</sub_title>
                <counts group_id="E1" events="68" subjects_affected="29" subjects_at_risk="75"/>
                <counts group_id="E2" events="40" subjects_affected="18" subjects_at_risk="75"/>
                <counts group_id="E3" events="16" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="20" subjects_affected="15" subjects_at_risk="75"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin - Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>BIPAP/NIPPV</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="75"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Petra Kaufmann, MD, MSc</name_or_title>
      <organization>Columbia University</organization>
      <phone>(212) 342-1252</phone>
      <email>pk88@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

